ImmunoCellular Therapeutics To Deliver Presentation on Cancer Stem Cells at Prestigious Immunotherapy Conference
January 30, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012. Dr. Singh's presentation will be titled "Targeting Cancer Stem Cells Via Immunotherapy" and will include an overview of ImmunoCellular's clinical activities to date including ICT-107, its lead program targeting cancer stem cells (CSC) in Glioblastoma. ICT-107 is currently in a randomized phase II clinical trial at multiple centers in the US. Company is also developing two additional products targeting CSCs in tumors via modulating immune system.

ImmunoCellular Therapeutics Provides Update on Phase II Clinical Trial of ICT-107 for the Treatment of Glioblastoma
January 23, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). The Company has initiated the trial in 23 centers and has received Institutional Review Board (IRB) approval from a total of 24 trial sites. The trial is expected to enroll approximately 160-200 patients to treat 102 patients with HLA-A1/A2 immunological subtypes. There are 115 patients enrolled in the study to date, ahead of the Company's schedule. Enrollment for the trial is expected to be completed by the second quarter of 2012 and an interim analysis is expected when 50% of events (32 deaths) have been observed.

ImmunoCellular Therapeutics to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
January 17, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), an emerging biotechnology company focused on developing novel-immune-based therapies, today announced that its President and CEO, Manish Singh Ph.D., will present at the Noble Financial Capital Markets Eighth Annual Equity Conference, being held at the Hard Rock Hotel in Hollywood, Florida from January 16-18, 2012.

ImmunoCellular Therapeutics Prices Underwritten Offering
January 10, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), an emerging biotechnology company focused on developing novel-immune-based therapies, announced today the pricing of an underwritten offering of 9,489,436 units, each unit consisting of one share of its common stock and a warrant to purchase one half of a share of its common stock, at a public offering price of $1.10 per unit. ImmunoCellular expects to receive net proceeds of approximately $9.4 million, after deducting the underwriting discount and estimated offering expenses. The warrants will have a five-year term and an exercise price equal to $1.41 per share. The offering is expected to close on January 13, 2012, subject to customary closing conditions.

ImmunoCellular Therapeutics Receives Notice of Allowance of Key U.S. Patent for Lead Product Candidate
October 10, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). The Company received notice that a patent titled "Cancer Vaccines and Vaccination Methods," which covers the method of delivery and the composition of the six antigens in ICT-107 that include TRP-2, MAGE-1, HER-2, IL-13 receptor a2, gp100 and AIM-2.

ImmunoCellular Therapeutics to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on October 6
October 6, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that the company will present at the Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on October 6, 2011 at the New York Academy of Medicine in New York City.

ImmunoCellular Therapeutics to Present at the Annual Meeting of the Congress of Neurological Surgeons
October 5, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based therapies, today announced that John Yu, MD, Chairman, will deliver an oral presentation at the Annual Meeting of the Congress of Neurological Surgeons. The abstract titled, "A Multi-Epitope Pulsed Dendritic Cell Vaccine (ICT-107) Targeting Glioblastoma Cancer Stem Cells Reduces the Cancer Stem Cell Population in Recurrent Tumor and Is Associated with Increased Progression-free Survival," will be presented at 2:54 p.m. today in room 151B at the Washington Convention Center in Washington, D.C.

NeoStem's Subsidiary, Progenitor Cell Therapy, and ImmunoCellular Therapeutics Enter Into a Manufacturing Agreement
October 3, 2011
ALLENDALE, N.J., LOS ANGELES and WOODLAND HILLS, Calif., Oct. 3, 2011 /PRNewswire/ -- Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized cell therapy services and development company and a wholly-owned subsidiary of NeoStem, Inc. (NYSE Amex: NBS), and ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC.ob - News) ("IMUC"), a clinical-stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer, announced today that IMUC has retained the services of PCT to serve as the second manufacturing site to produce ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma, for its Phase II clinical trial.

ImmunoCellular Therapeutics' ICT-107 Recognized As One Of Windhover's Top 10 Most Licensable Oncology Products
September 28, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that ICT-107 was recognized as one of Windhover's Top 10 licensable oncology products. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries.

ImmunoCellular Therapeutics to Present at the 13th Annual Rodman & Renshaw Global Investment Conference on September 13th
September 9, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that the company will present at the Rodman & Renshaw 13th Annual Global Investment Conference at the Waldorf Astoria in New York City on September 13th. The presentation will be given at 9:10 a.m. Eastern Daylight Time in Starlight South room.

ImmunoCellular Therapeutics gives Site Update for Phase II trial of ICT-107
September 7, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

ImmunoCellular Appoints Helen Kim to Board of Directors
August 29, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), announced today that Helen Kim has been appointed to the Company's Board of Directors and has been elected to be Chairperson of the Company's Product Strategic Committee. Ms. Kim currently serves on the Board of Directors at Sunesis Pharmaceuticals and as the Chief Business Officer of NGM Biopharmaceuticals, a privately held drug discovery company.

ImmunoCellular Therapeutics Issued New Patent for Diagnosis and Treatment of Ovarian Cancer and Multiple Myeloma
August 3, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer. Patent No. 1,204,683, entitled "Ovarian cancer cells and myeloma cell surface glycoproteins, antibodies thereto, and uses therof," covers aspects of the Company's monoclonal antibody ICT-69, which targets human multiple myeloma and ovarian cancer cells. ICT-69 is already covered in the United States and this patent expands coverage of Company's issued patent portfolio to nine.

ImmunoCellular Therapeutics to Present at 2nd World Cancer Vaccines Summit
June 22, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that Manish Singh Ph.D., the Company's President and CEO, will present at the 2nd World Cancer Vaccines Summit at the Radisson Hotel in Boston, MA on Thursday, June 23rd at 2:00 p.m. The presentation titled, "Multiple Antigen Vaccines for Glioblastoma" will feature ICT-107, ImmunoCellular's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme(GBM).

ImmunoCellular Therapeutics' Cancer Vaccine Technology Issued Key Patent
June 21, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license. Patent No. 7,939,090, entitled "System and method for the treatment of cancer, including cancers of the central nervous system," covers the combination of a dendritic cell based vaccine combined either before or concurrently with chemotherapy at the recurrence of the disease.

ImmunoCellular Therapeutics' ICT-107 Drug Candidate Featured in CBS Television News Story
June 8, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), announced today that ICT-107, its lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), was featured in a story on CBS New York's Channel 2 Newscast titled "Vaccine Could Kill Brain Tumors Using Body's Own Immune System." The story, by CBS' Dr. Max Gomez, a nine-time Emmy Award winning Medical Journalist, called ICT-107 a "promising vaccine" for the treatment of brain cancer.

ImmunoCellular Therapeutics and BioWa Announce License for the Research and Development of Therapeutic Antibodies in Cancer
June 2, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), and BioWa, Inc. (BioWa) today announced that they have entered into a agreement to provide IMUC with access to BioWa's patented POTELLIGENT ® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. Under the agreement Biowa will receive the right to certain antibody technology from IMUC and selected option rights to IMUC antibodies using the POTELLIGENT ® Technology.

ImmunoCellular Therapeutics to Present New Data from Phase I Study of ICT-107 in Glioblastoma Multiforme at ASCO 2011
May 24, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), today announced it will be presenting new data from the Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM). The abstract titled, "Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients with newly diagnosed glioblastoma" (Abstract #2042) will show that there is a correlation between the immunological response that ICT-107 generated in the form of antigens and both progression-free and overall survival. These observations suggest that targeting antigens highly expressed by cancer stem cells (CSCs) is a promising strategy for treating patients with glioblastoma.

ImmunoCellular Therapeutics Announces Updated Long-Term Disease-Free Survival Data from Phase I Study in Glioblastoma
May 5, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The data show 6 out of 16 (37.6%) newly diagnosed patients who received ICT-107 continue to show no tumor recurrence, with 3 of these patients (18.8%) remaining disease –free for almost four years while the other 3 patients have gone more than two and a half years disease-free. No new patients have shown disease recurrence since the last report of data in September, 2010. No treatment-related serious adverse events have been observed to date.

ImmunoCellular Therapeutics' Cancer Vaccine Safety and Preliminary Efficacy Results for Glioblastoma Trial Presented at American Academy of Neurology Annual Meeting
April 15, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) announced that Surasak Phuphanich, MD, Principal Investigator of the Phase I clinical trial of ImmunoCellular's lead dendritic cell cancer vaccine candidate for glioblastoma multiforme (GBM) presented safety and preliminary efficacy data yesterday at the American Academy of Neurology (AAN) 63rd Annual Meeting. Dr. Phuphanich, Director of the Neuro-Oncology Program in the Departments of Neurosurgery and Neurology and Professor of Medicine at Cedars-Sinai Medical Center, reported that of 16 newly-diagnosed patients with GBM enrolled between May 2007 and November 2009, 11 (69%) are still alive.

ImmunoCellular Therapeutics, Ltd. - ICT-107 Named One of the 100 Great Investigational Drugs for 2011
March 31, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that ICT-107 was selected by R&D Directions editors for the magazine's 10th annual list of "100 Great Investigational Drugs" featured as the cover article in the March 2011 issue. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme(GBM).

ImmunoCellular Therapeutics, Ltd. Announces $8.1 Million Financing
February 23, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), announced it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing. Upon the closing of the financing, ImmunoCellular will receive gross proceeds of approximately $8.1 million resulting from the sale of approximately 5.2 million units at a purchase price of $1.55 per unit.

ImmunoCellular Therapeutics to Present at the 13th Annual BIO CEO & Investor Conference
February 11, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that Manish Singh, Ph.D., the company's chief executive officer, will deliver a corporate overview at the upcoming 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh's presentation will take place on Monday, February 14, 2011 at 2:30 p.m. on the 4th Floor.

ImmunoCellular Therapeutics Announces First Patient Enrolled In Its Phase II Trial of ICT-107
February 02, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

ImmunoCellular Therapeutics Receives FDA Approval to Commence Phase II Trial of ICT-107
January 04, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) amendment to conduct a Phase II clinical trial in the U.S. of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

Press Archives